Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE-17: GSK3858279 for chronic diabetic peripheral neuropathic pain
jRCT2031230412Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of GSK3858279 in diabetic polyneuropathy (DPN) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline at Week 12 in weekly average of average daily pain intensity (NRS). Started Oct 2023; status: completed.
02
Drugs
GSK3858279
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on jRCT2031230412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230412.